Evidence map›Paper›PMID 33096803›Full record

ReviewPharmaceutics2020

Injectables and Depots to Prolong Drug Action of Proteins and Peptides.

Nkiruka Ibeanu, Raphael Egbu, Lesley Onyekuru, Hoda Javaheri, Peng Tee Khaw, Gareth R Williams, Steve Brocchini, Sahar Awwad

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 53 citations in OpenAlex.

  1. Piperazine-Functionalized Nanoparticles Enable Oral Insulin Delivery in Obese Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Advanced Formulation Approaches for Proteins.Handbook of experimental pharmacology · 2024
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nkiruka IbeanuSchool of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
Raphael EgbuSchool of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
Lesley OnyekuruSchool of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
Hoda JavaheriSchool of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
Peng Tee KhawNational Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 9EL, UK.
Gareth R WilliamsSchool of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
Steve BrocchiniSchool of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
Sahar AwwadSchool of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
Moorfields Eye Hospital NHS Foundation Trust · GBUniversity College London · GB

Funding

National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology -
6 · The paper itself

Abstract

Proteins and peptides have emerged in recent years to treat a wide range of multifaceted diseases such as cancer, diabetes and inflammation. The emergence of polypeptides has yielded advancements in the fields of biopharmaceutical production and formulation. Polypeptides often display poor pharmacokinetics, limited permeability across biological barriers, suboptimal biodistribution, and some proclivity for immunogenicity. Frequent administration of polypeptides is generally required to maintain adequate therapeutic levels, which can limit efficacy and compliance while increasing adverse reactions. Many strategies to increase the duration of action of therapeutic polypeptides have been described with many clinical products having been developed. This review describes approaches to optimise polypeptide delivery organised by the commonly used routes of administration. Future innovations in formulation may hold the key to the continued successful development of proteins and peptides with optimal clinical properties.

Indexed as

biologicsdrug deliveryhalf-lifeintravenousmucosalocularoralpeptidesproteinssubcutaneous

Identifiers

PMID33096803
PMCPMC7589296
OpenAlexW3094392837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.